Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30329716 | 1.00 | ERN1 (0.59) | ERN1MAPTHTTALDH1A1LMNA | |
| SCHEMBL12492120 | 0.87 | ERN1 (0.69) | ERN1MAPTHTTALDH1A1LMNA | |
| SCHEMBL13196182 | 0.84 | MAPT (0.53) | ERN1MAPTHTTALDH1A1LMNA | |
| SCHEMBL13625355 | 0.84 | ERN1 (0.58) | ERN1MAPTHTTALDH1A1LMNA | |
| SCHEMBL2553752 | 0.83 | LCK (0.51) | ERN1MAPTHTTALDH1A1LMNA | |
| SCHEMBL2553753 | 0.83 | LCK (0.51) | ERN1MAPTHTTALDH1A1LMNA | |
| SCHEMBL994720 | 0.82 | MEN1 (0.56) | MAPTHTTALDH1A1LMNAMEN1 | |
| SCHEMBL4756022 | 0.81 | ERN1 (0.63) | ERN1MAPTHTTALDH1A1LMNA | |
| SCHEMBL14198033 | 0.81 | MAPT (0.54) | ERN1MAPTHTTALDH1A1LMNA | |
| SCHEMBL14977336 | 0.80 | MAPT (0.60) | ERN1MAPTHTTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119192584-A | Siloxane modified terpyridine corrosion-resistant auxiliary agent and application thereof in preparation of intrinsic metal corrosion-resistant epoxy resin coating | 厦门大学深圳研究院 | 2024-12-27 | — | — | CN | claimed |
| CN-117209741-A | Preparation method of Schiff base catalyst and preparation method of polyglycolic acid | 中国科学院长春应用化学研究所 | 2023-12-12 | — | — | CN | claimed |
| CN-113563740-A | Anti-corrosion functional filler and preparation method and application thereof | 厦门大学 | 2021-10-29 | — | — | CN | claimed |
| CN-109134300-B | AIE compound and preparation method and application thereof | 晋中学院 | 2021-05-14 | — | — | CN | claimed |
| EP-2245132-B1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC NO 41424 (GB) | 2017-10-18 | — | — | EP | claimed |
| CN-106082199-A | A kind of graphene composite film and preparation method thereof | 烟台市烯能新材料股份有限公司 | 2016-11-09 | — | — | CN | claimed |
| CN-102015993-B | Encapsulated benefit agent | UNILEVER PLC | 2013-03-27 | — | — | CN | claimed |
| CN-102015993-A | Encapsulated benefit agent | UNILEVER PLC | 2011-04-13 | — | — | CN | claimed |
| EP-2245132-A1 | ENCAPSULATED BENEFIT AGENT | Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House (GB) | 2010-11-03 | — | — | EP | claimed |
| WO-2009103576-A1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC (GB) | 2009-08-27 | — | — | WO | claimed |
| CN-119192584-A | Siloxane modified terpyridine corrosion-resistant auxiliary agent and application thereof in preparation of intrinsic metal corrosion-resistant epoxy resin coating | 厦门大学深圳研究院 | 2024-12-27 | — | — | CN | disclosed |
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-118647610-A | Novel modulators of EHMT1 and EHMT2 and therapeutic uses thereof | 探戈医药股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-117343304-A | Double-center Schiff base catalyst and preparation method thereof, and preparation method of polyglycolic acid | 中国科学院长春应用化学研究所 | 2024-01-05 | — | — | CN | disclosed |
| CN-117343305-A | Tri-center Schiff base catalyst and preparation method thereof and preparation method of polyglycolide | 中国科学院长春应用化学研究所 | 2024-01-05 | — | — | CN | disclosed |
| WO-2001009122-A2 | SEROTONERGIC BENZOFURANS | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000044737-A1 | AMINOALKYLBENZOFURANS AS SEROTONIN (5-HT(2C)) AGONISTS | ELI LILLY AND COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| US-4281855-A | Pressure-sensitive or heat-sensitive recording material and novel 2,2-diarylchromeno compounds used therein | CIBA-GEIGY CORPORATION (US) | 1981-08-04 | — | — | US | disclosed |
| US-4183553-A | CARBONLESS COPYING | CIBA-GEIGY CORPORATION (US) | 1980-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | EHMT1, EHMT2, SHMT1 | ERN1 972/4885MAPT 2171/4885HTT 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.